Christopher Ballas

Christopher Ballas has a long and varied work experience in the biotechnology field. Christopher began their career in 2002 when they founded and served as Chief Scientific Officer for Gene-Ject, LLC. In 2004, they were the Director of Gene Therapy for Errant Gene Therapeutics, LLC. From 2006 to 2012, they were a Research Assistant Professor at Indiana University School of Medicine, where they conducted NIH-funded research projects and patented an ultrahigh throughput microinjection device. From 2012 to 2015, they were a Clinical Project Manager at Cook Research Inc. Christopher then moved to WuXi AppTec, where they served as Senior Director of Process Development, Tech Transfer, and Commercialization from 2015 to 2018, and as Director of Manufacturing, Advanced Therapies and Associate Director of Gene Mediated Cell Therapies from 2018 to 2019. In 2019, they Co-Founded Basilard BioTech, Inc. and also served as Senior Vice President of Manufacturing at Innovative Cellular Therapeutics (ICT). In 2022, they were a Scientific Advisory Board Member for Genezen, and in 2023 they became the Chief Technical Officer for Castle Creek Biosciences, Inc.

Christopher Ballas received their B.S. in Cell and Developmental Biology from Purdue University in 1990. Christopher then went on to pursue a Ph.D. in Cellular and Molecular Pathology from Vanderbilt University School of Medicine, which they completed in 1998.